nodes	percent_of_prediction	percent_of_DWPC	metapath
Glycopyrrolate—CHRM3—ureter—uterine cancer	0.0793	0.412	CbGeAlD
Glycopyrrolate—CHRM3—muscle of abdomen—uterine cancer	0.0571	0.297	CbGeAlD
Glycopyrrolate—CHRM3—exocrine gland—uterine cancer	0.0156	0.0813	CbGeAlD
Glycopyrrolate—CHRM5—epithelium—uterine cancer	0.0122	0.0632	CbGeAlD
Glycopyrrolate—CHRM3—smooth muscle tissue—uterine cancer	0.00655	0.0341	CbGeAlD
Glycopyrrolate—CHRM3—renal system—uterine cancer	0.0063	0.0328	CbGeAlD
Glycopyrrolate—CHRM1—female reproductive system—uterine cancer	0.00564	0.0293	CbGeAlD
Glycopyrrolate—CHRM3—female reproductive system—uterine cancer	0.00505	0.0263	CbGeAlD
Glycopyrrolate—CHRM3—female gonad—uterine cancer	0.00459	0.0239	CbGeAlD
Glycopyrrolate—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00244	0.00302	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.00243	0.00301	CcSEcCtD
Glycopyrrolate—Erythema—Dactinomycin—uterine cancer	0.0024	0.00297	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Progesterone—uterine cancer	0.0024	0.00297	CcSEcCtD
Glycopyrrolate—Fatigue—Progesterone—uterine cancer	0.00239	0.00296	CcSEcCtD
Glycopyrrolate—Pain—Progesterone—uterine cancer	0.00237	0.00294	CcSEcCtD
Glycopyrrolate—Constipation—Progesterone—uterine cancer	0.00237	0.00294	CcSEcCtD
Glycopyrrolate—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.00235	0.00291	CcSEcCtD
Glycopyrrolate—Atrioventricular block—Epirubicin—uterine cancer	0.0023	0.00285	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Progesterone—uterine cancer	0.00229	0.00283	CcSEcCtD
Glycopyrrolate—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.00227	0.00282	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Progesterone—uterine cancer	0.00227	0.00281	CcSEcCtD
Glycopyrrolate—Pneumonia—Etoposide—uterine cancer	0.00224	0.00277	CcSEcCtD
Glycopyrrolate—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.00224	0.00277	CcSEcCtD
Glycopyrrolate—Ventricular tachycardia—Epirubicin—uterine cancer	0.00223	0.00276	CcSEcCtD
Glycopyrrolate—Infestation NOS—Etoposide—uterine cancer	0.00223	0.00276	CcSEcCtD
Glycopyrrolate—Infestation—Etoposide—uterine cancer	0.00223	0.00276	CcSEcCtD
Glycopyrrolate—Injection site reaction—Epirubicin—uterine cancer	0.00222	0.00274	CcSEcCtD
Glycopyrrolate—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.00221	0.00274	CcSEcCtD
Glycopyrrolate—Urticaria—Progesterone—uterine cancer	0.0022	0.00273	CcSEcCtD
Glycopyrrolate—Abdominal pain—Progesterone—uterine cancer	0.00219	0.00272	CcSEcCtD
Glycopyrrolate—Body temperature increased—Progesterone—uterine cancer	0.00219	0.00272	CcSEcCtD
Glycopyrrolate—Cystitis noninfective—Epirubicin—uterine cancer	0.00218	0.0027	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00217	0.00269	CcSEcCtD
Glycopyrrolate—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00217	0.00268	CcSEcCtD
Glycopyrrolate—Cystitis—Epirubicin—uterine cancer	0.00215	0.00267	CcSEcCtD
Glycopyrrolate—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.00215	0.00266	CcSEcCtD
Glycopyrrolate—Atrioventricular block—Doxorubicin—uterine cancer	0.00213	0.00263	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00207	0.00257	CcSEcCtD
Glycopyrrolate—Ventricular tachycardia—Doxorubicin—uterine cancer	0.00206	0.00255	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00206	0.00255	CcSEcCtD
Glycopyrrolate—Injection site reaction—Doxorubicin—uterine cancer	0.00205	0.00254	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Progesterone—uterine cancer	0.00204	0.00253	CcSEcCtD
Glycopyrrolate—Bladder pain—Epirubicin—uterine cancer	0.00202	0.0025	CcSEcCtD
Glycopyrrolate—Cystitis noninfective—Doxorubicin—uterine cancer	0.00202	0.0025	CcSEcCtD
Glycopyrrolate—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.002	0.00247	CcSEcCtD
Glycopyrrolate—Cystitis—Doxorubicin—uterine cancer	0.00199	0.00247	CcSEcCtD
Glycopyrrolate—Asthenia—Progesterone—uterine cancer	0.00199	0.00246	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Etoposide—uterine cancer	0.00199	0.00246	CcSEcCtD
Glycopyrrolate—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.00199	0.00246	CcSEcCtD
Glycopyrrolate—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00199	0.00246	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Etoposide—uterine cancer	0.00197	0.00244	CcSEcCtD
Glycopyrrolate—Pruritus—Progesterone—uterine cancer	0.00196	0.00243	CcSEcCtD
Glycopyrrolate—Oedema—Dactinomycin—uterine cancer	0.00196	0.00243	CcSEcCtD
Glycopyrrolate—Urethral disorder—Etoposide—uterine cancer	0.00196	0.00242	CcSEcCtD
Glycopyrrolate—Infection—Dactinomycin—uterine cancer	0.00195	0.00241	CcSEcCtD
Glycopyrrolate—Bladder pain—Doxorubicin—uterine cancer	0.00187	0.00231	CcSEcCtD
Glycopyrrolate—Flushing—Etoposide—uterine cancer	0.00185	0.0023	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Etoposide—uterine cancer	0.00185	0.0023	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00185	0.00229	CcSEcCtD
Glycopyrrolate—Dizziness—Progesterone—uterine cancer	0.00183	0.00227	CcSEcCtD
Glycopyrrolate—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.0018	0.00223	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Etoposide—uterine cancer	0.0018	0.00223	CcSEcCtD
Glycopyrrolate—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.00178	0.0022	CcSEcCtD
Glycopyrrolate—Vomiting—Progesterone—uterine cancer	0.00176	0.00218	CcSEcCtD
Glycopyrrolate—Rash—Progesterone—uterine cancer	0.00175	0.00217	CcSEcCtD
Glycopyrrolate—Dermatitis—Progesterone—uterine cancer	0.00175	0.00216	CcSEcCtD
Glycopyrrolate—Headache—Progesterone—uterine cancer	0.00174	0.00215	CcSEcCtD
Glycopyrrolate—Dysgeusia—Etoposide—uterine cancer	0.0017	0.00211	CcSEcCtD
Glycopyrrolate—Fatigue—Dactinomycin—uterine cancer	0.00169	0.00209	CcSEcCtD
Glycopyrrolate—Pain—Dactinomycin—uterine cancer	0.00168	0.00208	CcSEcCtD
Glycopyrrolate—Anaphylactoid reaction—Epirubicin—uterine cancer	0.00167	0.00207	CcSEcCtD
Glycopyrrolate—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00166	0.00206	CcSEcCtD
Glycopyrrolate—Nausea—Progesterone—uterine cancer	0.00165	0.00204	CcSEcCtD
Glycopyrrolate—Pain in extremity—Epirubicin—uterine cancer	0.00162	0.002	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Dactinomycin—uterine cancer	0.00162	0.002	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Dactinomycin—uterine cancer	0.0016	0.00199	CcSEcCtD
Glycopyrrolate—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.0016	0.00198	CcSEcCtD
Glycopyrrolate—Affect lability—Epirubicin—uterine cancer	0.00159	0.00197	CcSEcCtD
Glycopyrrolate—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00159	0.00196	CcSEcCtD
Glycopyrrolate—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00158	0.00196	CcSEcCtD
Glycopyrrolate—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00158	0.00195	CcSEcCtD
Glycopyrrolate—Body temperature increased—Dactinomycin—uterine cancer	0.00155	0.00192	CcSEcCtD
Glycopyrrolate—Abdominal pain—Dactinomycin—uterine cancer	0.00155	0.00192	CcSEcCtD
Glycopyrrolate—Anaphylactoid reaction—Doxorubicin—uterine cancer	0.00155	0.00192	CcSEcCtD
Glycopyrrolate—Cardiac arrest—Epirubicin—uterine cancer	0.00154	0.00191	CcSEcCtD
Glycopyrrolate—Mood swings—Epirubicin—uterine cancer	0.00153	0.0019	CcSEcCtD
Glycopyrrolate—Convulsion—Etoposide—uterine cancer	0.00151	0.00187	CcSEcCtD
Glycopyrrolate—Dehydration—Epirubicin—uterine cancer	0.00151	0.00186	CcSEcCtD
Glycopyrrolate—Hypertension—Etoposide—uterine cancer	0.0015	0.00186	CcSEcCtD
Glycopyrrolate—Pain in extremity—Doxorubicin—uterine cancer	0.0015	0.00185	CcSEcCtD
Glycopyrrolate—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00149	0.00185	CcSEcCtD
Glycopyrrolate—Dry skin—Epirubicin—uterine cancer	0.00148	0.00184	CcSEcCtD
Glycopyrrolate—Affect lability—Doxorubicin—uterine cancer	0.00147	0.00183	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.00147	0.00182	CcSEcCtD
Glycopyrrolate—Nasopharyngitis—Epirubicin—uterine cancer	0.00145	0.00179	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Dactinomycin—uterine cancer	0.00144	0.00179	CcSEcCtD
Glycopyrrolate—Confusional state—Etoposide—uterine cancer	0.00143	0.00177	CcSEcCtD
Glycopyrrolate—Cardiac arrest—Doxorubicin—uterine cancer	0.00142	0.00176	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Etoposide—uterine cancer	0.00142	0.00176	CcSEcCtD
Glycopyrrolate—Mood swings—Doxorubicin—uterine cancer	0.00142	0.00176	CcSEcCtD
Glycopyrrolate—Infection—Etoposide—uterine cancer	0.00141	0.00175	CcSEcCtD
Glycopyrrolate—Abdominal distension—Epirubicin—uterine cancer	0.00141	0.00174	CcSEcCtD
Glycopyrrolate—Asthenia—Dactinomycin—uterine cancer	0.00141	0.00174	CcSEcCtD
Glycopyrrolate—Dehydration—Doxorubicin—uterine cancer	0.00139	0.00172	CcSEcCtD
Glycopyrrolate—Tachycardia—Etoposide—uterine cancer	0.00139	0.00172	CcSEcCtD
Glycopyrrolate—Skin disorder—Etoposide—uterine cancer	0.00138	0.00171	CcSEcCtD
Glycopyrrolate—Dry skin—Doxorubicin—uterine cancer	0.00137	0.0017	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Etoposide—uterine cancer	0.00137	0.0017	CcSEcCtD
Glycopyrrolate—Nasopharyngitis—Doxorubicin—uterine cancer	0.00134	0.00166	CcSEcCtD
Glycopyrrolate—Hypotension—Etoposide—uterine cancer	0.00133	0.00164	CcSEcCtD
Glycopyrrolate—Dysuria—Epirubicin—uterine cancer	0.00131	0.00162	CcSEcCtD
Glycopyrrolate—Abdominal distension—Doxorubicin—uterine cancer	0.0013	0.00161	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Epirubicin—uterine cancer	0.0013	0.00161	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Epirubicin—uterine cancer	0.00126	0.00156	CcSEcCtD
Glycopyrrolate—Somnolence—Etoposide—uterine cancer	0.00126	0.00156	CcSEcCtD
Glycopyrrolate—Pneumonia—Epirubicin—uterine cancer	0.00125	0.00155	CcSEcCtD
Glycopyrrolate—Infestation NOS—Epirubicin—uterine cancer	0.00125	0.00154	CcSEcCtD
Glycopyrrolate—Infestation—Epirubicin—uterine cancer	0.00125	0.00154	CcSEcCtD
Glycopyrrolate—Drowsiness—Epirubicin—uterine cancer	0.00125	0.00154	CcSEcCtD
Glycopyrrolate—Vomiting—Dactinomycin—uterine cancer	0.00125	0.00154	CcSEcCtD
Glycopyrrolate—Rash—Dactinomycin—uterine cancer	0.00124	0.00153	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Etoposide—uterine cancer	0.00123	0.00152	CcSEcCtD
Glycopyrrolate—Fatigue—Etoposide—uterine cancer	0.00122	0.00152	CcSEcCtD
Glycopyrrolate—Constipation—Etoposide—uterine cancer	0.00121	0.0015	CcSEcCtD
Glycopyrrolate—Pain—Etoposide—uterine cancer	0.00121	0.0015	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Epirubicin—uterine cancer	0.00121	0.0015	CcSEcCtD
Glycopyrrolate—Dysuria—Doxorubicin—uterine cancer	0.00121	0.0015	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.0012	0.00149	CcSEcCtD
Glycopyrrolate—Sweating—Epirubicin—uterine cancer	0.0012	0.00148	CcSEcCtD
Glycopyrrolate—Epistaxis—Epirubicin—uterine cancer	0.00118	0.00146	CcSEcCtD
Glycopyrrolate—Sinusitis—Epirubicin—uterine cancer	0.00117	0.00145	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Etoposide—uterine cancer	0.00117	0.00145	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Doxorubicin—uterine cancer	0.00117	0.00145	CcSEcCtD
Glycopyrrolate—Nausea—Dactinomycin—uterine cancer	0.00116	0.00144	CcSEcCtD
Glycopyrrolate—Pneumonia—Doxorubicin—uterine cancer	0.00116	0.00144	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Etoposide—uterine cancer	0.00116	0.00144	CcSEcCtD
Glycopyrrolate—Drowsiness—Doxorubicin—uterine cancer	0.00115	0.00143	CcSEcCtD
Glycopyrrolate—Infestation NOS—Doxorubicin—uterine cancer	0.00115	0.00143	CcSEcCtD
Glycopyrrolate—Infestation—Doxorubicin—uterine cancer	0.00115	0.00143	CcSEcCtD
Glycopyrrolate—Urticaria—Etoposide—uterine cancer	0.00113	0.0014	CcSEcCtD
Glycopyrrolate—Rhinitis—Epirubicin—uterine cancer	0.00112	0.00139	CcSEcCtD
Glycopyrrolate—Abdominal pain—Etoposide—uterine cancer	0.00112	0.00139	CcSEcCtD
Glycopyrrolate—Body temperature increased—Etoposide—uterine cancer	0.00112	0.00139	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Doxorubicin—uterine cancer	0.00112	0.00139	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Epirubicin—uterine cancer	0.00111	0.00138	CcSEcCtD
Glycopyrrolate—Sweating—Doxorubicin—uterine cancer	0.00111	0.00137	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Epirubicin—uterine cancer	0.00111	0.00137	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Epirubicin—uterine cancer	0.0011	0.00136	CcSEcCtD
Glycopyrrolate—Urethral disorder—Epirubicin—uterine cancer	0.0011	0.00136	CcSEcCtD
Glycopyrrolate—Epistaxis—Doxorubicin—uterine cancer	0.00109	0.00135	CcSEcCtD
Glycopyrrolate—Sinusitis—Doxorubicin—uterine cancer	0.00108	0.00134	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Etoposide—uterine cancer	0.00105	0.00129	CcSEcCtD
Glycopyrrolate—Flushing—Epirubicin—uterine cancer	0.00104	0.00129	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Epirubicin—uterine cancer	0.00104	0.00129	CcSEcCtD
Glycopyrrolate—Rhinitis—Doxorubicin—uterine cancer	0.00104	0.00129	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Doxorubicin—uterine cancer	0.00103	0.00128	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Doxorubicin—uterine cancer	0.00102	0.00127	CcSEcCtD
Glycopyrrolate—Asthenia—Etoposide—uterine cancer	0.00102	0.00126	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Doxorubicin—uterine cancer	0.00102	0.00126	CcSEcCtD
Glycopyrrolate—Urethral disorder—Doxorubicin—uterine cancer	0.00102	0.00126	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Epirubicin—uterine cancer	0.00101	0.00125	CcSEcCtD
Glycopyrrolate—Pruritus—Etoposide—uterine cancer	0.001	0.00124	CcSEcCtD
Glycopyrrolate—Mental disorder—Epirubicin—uterine cancer	0.000981	0.00121	CcSEcCtD
Glycopyrrolate—Erythema—Epirubicin—uterine cancer	0.000975	0.00121	CcSEcCtD
Glycopyrrolate—Malnutrition—Epirubicin—uterine cancer	0.000975	0.00121	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Doxorubicin—uterine cancer	0.000962	0.00119	CcSEcCtD
Glycopyrrolate—Flushing—Doxorubicin—uterine cancer	0.000962	0.00119	CcSEcCtD
Glycopyrrolate—Flatulence—Epirubicin—uterine cancer	0.000961	0.00119	CcSEcCtD
Glycopyrrolate—Tension—Epirubicin—uterine cancer	0.000957	0.00118	CcSEcCtD
Glycopyrrolate—Dysgeusia—Epirubicin—uterine cancer	0.000955	0.00118	CcSEcCtD
Glycopyrrolate—Nervousness—Epirubicin—uterine cancer	0.000947	0.00117	CcSEcCtD
Glycopyrrolate—Dizziness—Etoposide—uterine cancer	0.000939	0.00116	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Doxorubicin—uterine cancer	0.000934	0.00116	CcSEcCtD
Glycopyrrolate—Vision blurred—Epirubicin—uterine cancer	0.000919	0.00114	CcSEcCtD
Glycopyrrolate—Mental disorder—Doxorubicin—uterine cancer	0.000908	0.00112	CcSEcCtD
Glycopyrrolate—Vomiting—Etoposide—uterine cancer	0.000902	0.00112	CcSEcCtD
Glycopyrrolate—Erythema—Doxorubicin—uterine cancer	0.000902	0.00112	CcSEcCtD
Glycopyrrolate—Malnutrition—Doxorubicin—uterine cancer	0.000902	0.00112	CcSEcCtD
Glycopyrrolate—Agitation—Epirubicin—uterine cancer	0.000896	0.00111	CcSEcCtD
Glycopyrrolate—Rash—Etoposide—uterine cancer	0.000895	0.00111	CcSEcCtD
Glycopyrrolate—Dermatitis—Etoposide—uterine cancer	0.000894	0.00111	CcSEcCtD
Glycopyrrolate—Headache—Etoposide—uterine cancer	0.000889	0.0011	CcSEcCtD
Glycopyrrolate—Flatulence—Doxorubicin—uterine cancer	0.000889	0.0011	CcSEcCtD
Glycopyrrolate—Tension—Doxorubicin—uterine cancer	0.000885	0.0011	CcSEcCtD
Glycopyrrolate—Dysgeusia—Doxorubicin—uterine cancer	0.000883	0.00109	CcSEcCtD
Glycopyrrolate—Nervousness—Doxorubicin—uterine cancer	0.000876	0.00108	CcSEcCtD
Glycopyrrolate—Palpitations—Epirubicin—uterine cancer	0.000862	0.00107	CcSEcCtD
Glycopyrrolate—Vision blurred—Doxorubicin—uterine cancer	0.00085	0.00105	CcSEcCtD
Glycopyrrolate—Convulsion—Epirubicin—uterine cancer	0.000845	0.00105	CcSEcCtD
Glycopyrrolate—Nausea—Etoposide—uterine cancer	0.000843	0.00104	CcSEcCtD
Glycopyrrolate—Hypertension—Epirubicin—uterine cancer	0.000842	0.00104	CcSEcCtD
Glycopyrrolate—Agitation—Doxorubicin—uterine cancer	0.000829	0.00103	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000824	0.00102	CcSEcCtD
Glycopyrrolate—Dry mouth—Epirubicin—uterine cancer	0.000812	0.001	CcSEcCtD
Glycopyrrolate—Confusional state—Epirubicin—uterine cancer	0.000802	0.000993	CcSEcCtD
Glycopyrrolate—Palpitations—Doxorubicin—uterine cancer	0.000797	0.000987	CcSEcCtD
Glycopyrrolate—Oedema—Epirubicin—uterine cancer	0.000796	0.000985	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Epirubicin—uterine cancer	0.000796	0.000985	CcSEcCtD
Glycopyrrolate—Infection—Epirubicin—uterine cancer	0.00079	0.000979	CcSEcCtD
Glycopyrrolate—Convulsion—Doxorubicin—uterine cancer	0.000782	0.000968	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Epirubicin—uterine cancer	0.00078	0.000966	CcSEcCtD
Glycopyrrolate—Hypertension—Doxorubicin—uterine cancer	0.000779	0.000964	CcSEcCtD
Glycopyrrolate—Tachycardia—Epirubicin—uterine cancer	0.000777	0.000961	CcSEcCtD
Glycopyrrolate—Skin disorder—Epirubicin—uterine cancer	0.000773	0.000957	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Epirubicin—uterine cancer	0.000769	0.000952	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000763	0.000944	CcSEcCtD
Glycopyrrolate—Dry mouth—Doxorubicin—uterine cancer	0.000751	0.00093	CcSEcCtD
Glycopyrrolate—Hypotension—Epirubicin—uterine cancer	0.000743	0.00092	CcSEcCtD
Glycopyrrolate—Confusional state—Doxorubicin—uterine cancer	0.000742	0.000919	CcSEcCtD
Glycopyrrolate—Oedema—Doxorubicin—uterine cancer	0.000736	0.000911	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Doxorubicin—uterine cancer	0.000736	0.000911	CcSEcCtD
Glycopyrrolate—Infection—Doxorubicin—uterine cancer	0.000731	0.000905	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Doxorubicin—uterine cancer	0.000722	0.000894	CcSEcCtD
Glycopyrrolate—Insomnia—Epirubicin—uterine cancer	0.00072	0.000891	CcSEcCtD
Glycopyrrolate—Tachycardia—Doxorubicin—uterine cancer	0.000718	0.00089	CcSEcCtD
Glycopyrrolate—Skin disorder—Doxorubicin—uterine cancer	0.000715	0.000885	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Doxorubicin—uterine cancer	0.000712	0.000881	CcSEcCtD
Glycopyrrolate—Somnolence—Epirubicin—uterine cancer	0.000707	0.000876	CcSEcCtD
Glycopyrrolate—Dyspepsia—Epirubicin—uterine cancer	0.0007	0.000867	CcSEcCtD
Glycopyrrolate—Hypotension—Doxorubicin—uterine cancer	0.000688	0.000852	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000687	0.00085	CcSEcCtD
Glycopyrrolate—Fatigue—Epirubicin—uterine cancer	0.000686	0.000849	CcSEcCtD
Glycopyrrolate—Constipation—Epirubicin—uterine cancer	0.00068	0.000842	CcSEcCtD
Glycopyrrolate—Pain—Epirubicin—uterine cancer	0.00068	0.000842	CcSEcCtD
Glycopyrrolate—Insomnia—Doxorubicin—uterine cancer	0.000666	0.000824	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Epirubicin—uterine cancer	0.000656	0.000812	CcSEcCtD
Glycopyrrolate—Somnolence—Doxorubicin—uterine cancer	0.000654	0.00081	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Epirubicin—uterine cancer	0.000651	0.000805	CcSEcCtD
Glycopyrrolate—Dyspepsia—Doxorubicin—uterine cancer	0.000648	0.000802	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000636	0.000787	CcSEcCtD
Glycopyrrolate—Fatigue—Doxorubicin—uterine cancer	0.000635	0.000786	CcSEcCtD
Glycopyrrolate—Urticaria—Epirubicin—uterine cancer	0.000632	0.000783	CcSEcCtD
Glycopyrrolate—Pain—Doxorubicin—uterine cancer	0.00063	0.000779	CcSEcCtD
Glycopyrrolate—Constipation—Doxorubicin—uterine cancer	0.00063	0.000779	CcSEcCtD
Glycopyrrolate—Abdominal pain—Epirubicin—uterine cancer	0.000629	0.000779	CcSEcCtD
Glycopyrrolate—Body temperature increased—Epirubicin—uterine cancer	0.000629	0.000779	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Doxorubicin—uterine cancer	0.000607	0.000751	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000602	0.000745	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Epirubicin—uterine cancer	0.000586	0.000726	CcSEcCtD
Glycopyrrolate—Urticaria—Doxorubicin—uterine cancer	0.000585	0.000724	CcSEcCtD
Glycopyrrolate—Abdominal pain—Doxorubicin—uterine cancer	0.000582	0.000721	CcSEcCtD
Glycopyrrolate—Body temperature increased—Doxorubicin—uterine cancer	0.000582	0.000721	CcSEcCtD
Glycopyrrolate—Asthenia—Epirubicin—uterine cancer	0.000571	0.000707	CcSEcCtD
Glycopyrrolate—Pruritus—Epirubicin—uterine cancer	0.000563	0.000697	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Doxorubicin—uterine cancer	0.000542	0.000672	CcSEcCtD
Glycopyrrolate—Asthenia—Doxorubicin—uterine cancer	0.000528	0.000654	CcSEcCtD
Glycopyrrolate—Dizziness—Epirubicin—uterine cancer	0.000526	0.000651	CcSEcCtD
Glycopyrrolate—Pruritus—Doxorubicin—uterine cancer	0.000521	0.000645	CcSEcCtD
Glycopyrrolate—Vomiting—Epirubicin—uterine cancer	0.000506	0.000626	CcSEcCtD
Glycopyrrolate—Rash—Epirubicin—uterine cancer	0.000502	0.000621	CcSEcCtD
Glycopyrrolate—Dermatitis—Epirubicin—uterine cancer	0.000501	0.000621	CcSEcCtD
Glycopyrrolate—Headache—Epirubicin—uterine cancer	0.000498	0.000617	CcSEcCtD
Glycopyrrolate—Dizziness—Doxorubicin—uterine cancer	0.000487	0.000603	CcSEcCtD
Glycopyrrolate—Nausea—Epirubicin—uterine cancer	0.000473	0.000585	CcSEcCtD
Glycopyrrolate—Vomiting—Doxorubicin—uterine cancer	0.000468	0.00058	CcSEcCtD
Glycopyrrolate—Rash—Doxorubicin—uterine cancer	0.000464	0.000575	CcSEcCtD
Glycopyrrolate—Dermatitis—Doxorubicin—uterine cancer	0.000464	0.000574	CcSEcCtD
Glycopyrrolate—Headache—Doxorubicin—uterine cancer	0.000461	0.000571	CcSEcCtD
Glycopyrrolate—Nausea—Doxorubicin—uterine cancer	0.000437	0.000541	CcSEcCtD
